Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2014

View Archived Issues

Third milestone achieved in GenVec and Novartis collaboration

UCB and MRC Technology sign exclusive license agreement

Preclinical characterization of a novel N-glucoside SGLT2 inhibitor

Shire reviews activities of fourth quarter 2013

Investigators identify a potential prognostic marker for CRPC

Sato Pharmaceutical discloses new SLC22A12 inhibitors

Novel GPR119 receptor agonists patented

Results presented from phase I study of ridaforolimus and vorinostat in RCC

Endo Pharmaceuticals discloses new agents for cancer

Soligenix receives grant from NIAID to support development of SGX-943 for melioidosis

Scientists at Sunshine Lake Pharma synthesize novel NS5A inhibitors

Japanese researchers claim new prostanoid EP1 receptor antagonists

FDA issues complete response letters regarding sNDAs for Xarelto

Proximagen designs new PAR-2 antagonists

ViroMed granted FDA orphan drug designation for VM-202-ALS, launches phase I/II trial

New PHD2 inhibitors presented by Taisho Pharmaceutical for anemia

EpiTherapeutics prepares and tests novel KDM5 inhibitors

Novel Ca(v)3.2. blockers disclosed by Kyowa Hakko Kirin

Oxford BioMedica and Sanofi amend terms of agreement for gene-based ocular disease drugs

Cangene shareholders in favor of acquisition

Forest Laboratories to discontinue sale of Namenda tablets

NCI and FDA reach SPA agreement for phase III trial of Syndax's entinostat

Phase III study of mepolizumab in eosinophilic granulomatosis with polyangiitis begins

European COMP recommends orphan drug designation for ISIS-TTRRx

Millennium Pharmaceuticals to conduct PET imaging study of [68Ga]MLN-6907

FDA approves BioMarin's Vimizim for MPS IVA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...